3[3]Vivianis S,Bonadonna G,Santoro A,et al.Altemating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease ten-year results[J].Clin Oncol,1996,14:1421-1430.
4[4]Connors JM,Klimo P,Adams G,et al.Treatment of advanced Hodgkin's disease with chemotherapy-comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD a report from the National Cancer Institute Canada Clinical Trial Group[J].Clin Oncol,1997,15:1638-1645.
5[9]Mok TS,Steinberg J,Chen AT,et al. Application of the international prognostic index in a study of Chinese patients with non-HokgKin's lymphoma and a high incidence of primary extranodal lymphoma[J].Caner,1998,82:2438-2448.
6[10]Ship MA,Mauch PA,Harris NL.Non-Hodgkin's lymphoma[A].Wilson LD,Kacinski BM,Edelson RL,et al. Cutaneoyus T-cell lymphomal[A].Deangelis LM,Yahalom J.Primary central nervous system lymphoma[A].Devita VT Jr,Hellman S,Rosenberg SA.Cancer principles practice of oncology[M].5th Edition. JB Lippincott.Philadelphia,1997.2165-2241.
7[11]Donato V,Iacari V,Zuplo A,et al.Radiation therapy and chemotherpy in the treatment of head and neck extranodal non Hodgkin's lympoma in early stage with a high grade of malignancy[J].Anticancer Research,1998,18:547-554.
8[13]Younes A,Romaguera J,Mesina O,et al.Paclitaxel plus highdose cyclophosphamide with G-CSF support in patients with relapsed and refractory aggressive non-Hodgkin's lymphoma[J].Br J Haematol,1998,103:678-683.
9[14]Tulpule A,Schiller G,Harvey Buchanan LA,et al.Cladribine in the treatment of advanced relapsed or refractory low and intermediate grade non-Hodgkin's lynphoma[J].Cancer,1998,83:2370-2376.
